Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials

• Main Authors: Shawn G. Kwatra (Author), Saakshi Khattri (Author), Ahmad Z. Amin (Author), Roberto Ranza (Author), Blair Kaplan (Author), Linyu Shi (Author), Byron Padilla (Author), Ahmed M. Soliman (Author), Dennis McGonagle (Author)
• Formato: Libro
• Publicado: Adis, Springer Healthcare, 2024-05-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Abstract Introduction The presence (vs absence) of enthesitis/dactylitis is associated with greater psoriatic arthritis (PsA) activity and reduced health-related quality of life. Risankizumab, an interleukin 23 antagonist, demonstrated superior treatment efficacy over placebo in patients with PsA, i...